biostudies-literatureUnknown45Bjartell A<h4>Background</h4>Prostate cancer has a multifaceted treatment pattern. Evidence is lacking for optimal treatment sequences for metastatic castration-resistant prostate cancer (mCRPC).<h4>Objective</h4>To increase the understanding of real-world treatment pathways and outcomes in patients with mCRPC.<h4>Design setting and participants</h4>A prospective, noninterventional, real-world analysis of 3003 patients with mCRPC in the Prostate Cancer Registry (PCR; NCT02236637) from June 14, 2013 to July 9, 2018 was conducted.<h4>Intervention</h4>Patients received first- and second-line hormonal treatment and chemotherapy as follows: abiraterone acetate plus prednisone (abiraterone)-docetaxel (ABI-DOCE), abiraterone-enzalutamide (ABI-ENZA), abiraterone-radium-223 (ABI-RAD), docetaxel-abiraterone (European urology open science12-22https://www.ebi.ac.uk/biostudies/studies/S-EPMC9637537biostudies-literatureReal-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry.PMC9637537Lukac MPeer AWapenaar RParikh OChowdhury SSmith EBennamoun MGarcia Freire CEcke TKramer GZurawski BCosta LCicin IBjartell AWerbrouck PLjungberg BGalli LfalseReal-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry.<h4>Background</h4>Prostate cancer has a multifaceted treatment pattern. Evidence is lacking for optimal treatment sequences for metastatic castration-resistant prostate cancer (mCRPC).<h4>Objective</h4>To increase the understanding of real-world treatment pathways and outcomes in patients with mCRPC.<h4>Design setting and participants</h4>A prospective, noninterventional, real-world analysis of 3003 patients with mCRPC in the Prostate Cancer Registry (PCR; NCT02236637) from June 14, 2013 to July 9, 2018 was conducted.<h4>Intervention</h4>Patients received first- and second-line hormonal treatment and chemotherapy as follows: abiraterone acetate plus prednisone (abiraterone)-docetaxel (ABI-DOCE), abiraterone-enzalutamide (ABI-ENZA), abiraterone-radium-223 (ABI-RAD), docetaxel-abiraterone (2022-01-01T00:00:00Z2022 Nov2025-04-19T23:16:02.613Z2025-04-19T23:16:02.613ZS-EPMC96375373635366110.1016/j.euros.2022.08.018